Evidence map›Paper›PMID 36845149›Full record

ReviewFrontiers in immunology2023

Targeting β-glucans, vital components of the

Mengyan Wang, Zhongdong Zhang, Xiaotian Dong, Biao Zhu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. β-Glucans,Journal of fungi (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Characterization of theAntimicrobial agents and chemotherapy · 2024
    Article
  5. Glucans: A Therapeutic Alternative for Sepsis Treatment.Journal of immunology research · 2024
    Review
  6. Lung Epithelial Cell Line Immune Responses toJournal of fungi (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Mengyan WangDepartment II of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, China.
Zhongdong ZhangDepartment II of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, China.
Xiaotian DongDepartment of Clinical Laboratory, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Biao ZhuDepartment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Hangzhou Xixi hospital · CNState Key Laboratory of Diagnosis and Treatment of Infectious DiseasesZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-glucan is the most abundant polysaccharide in the cell wall of

Indexed as

beta-GlucansPneumocystisPneumonia, PneumocystisCell WallGlucansbeta-GlucansGlucansinflammatoryinitial immunityPneumocystistherapyβ-glucan

Identifiers

PMID36845149
PMCPMC9947646
OpenAlexW4319750978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.